Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

Lina van der Straten(Erasmus MC), Mark‐David Levin(Albert Schweitzer Hospital), Peter E. Westerweel(Albert Schweitzer Ziekenhuis), Arnon P. Kater(Amsterdam University Medical Centers), Avinash G. Dinmohamed(Netherlands Comprehensive Cancer Organisation), Anton W. Langerak(Erasmus MC), Jürgen Riedl(Albert Schweitzer Ziekenhuis), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
Leukemia & lymphoma/Leukemia and lymphoma
April 4, 2018
10.1080/10428194.2018.1452215
Cited by 1

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
|Leukemia|2019|260